Halbert Hargrove Global Advisors, LLC Arcus Biosciences, Inc. Transaction History
Halbert Hargrove Global Advisors, LLC
- $2.02 Billion
- Q3 2025
A detailed history of Halbert Hargrove Global Advisors, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Halbert Hargrove Global Advisors, LLC holds 180 shares of RCUS stock, worth $3,144. This represents 0.0% of its overall portfolio holdings.
Number of Shares
180Holding current value
$3,144% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RCUS
# of Institutions
212Shares Held
67MCall Options Held
3.18MPut Options Held
167K-
Black Rock Inc. New York, NY9.76MShares$171 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.56MShares$115 Million0.0% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.97MShares$104 Million0.11% of portfolio
-
Woodline Partners LP San Francisco, CA4MShares$69.9 Million0.19% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$64.4 Million1.03% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.26B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...